- Conditions
- Advanced Solid Tumors
- Interventions
- LCL161
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 18,744
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer
- Interventions
- aminocamptothecin colloidal dispersion
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumors, Acute Myeloid Leukemia
- Interventions
- Gilteritinib
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Baltimore, Maryland • New York, New York + 3 more
- Conditions
- Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
- Interventions
- Stem Cell Radiotherapy (ScRT) and Temozolomide
- Radiation
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumors, Malignant Neoplasm
- Interventions
- MK-3120
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Miami, Florida • Hackensack, New Jersey + 4 more
- Conditions
- Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
- Interventions
- ATI-1123 (active drug = docetaxel)
- Drug
- Lead sponsor
- Azaya Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Interventions
- Behavioral Dietary Intervention, Educational Intervention, Questionnaire Administration
- Behavioral · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Colon Cancer, Colorectal Cancer
- Interventions
- EPO906, Celecoxib
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Participants
- Interventions
- Metformin, Sevabertinib (BAY 2927088)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer, Peritoneal Cancer, Head and Neck Cancer, HNSCC, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- COTI2, Cisplatin
- Drug
- Lead sponsor
- Critical Outcome Technologies Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- West Nile Virus
- Interventions
- WN/DEN4Δ30 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Burlington, Vermont
- Conditions
- Tumors, Neoplasms, Cancer
- Interventions
- APS001F, Flucytosine (5-FC), 10% maltose
- Drug
- Lead sponsor
- Anaeropharma Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Houston, Texas
- Conditions
- Meningitis, Meningococcal
- Interventions
- rLP2086 vaccine or control
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Type 2 Diabetes
- Interventions
- XOMA 052, Placebo
- Drug
- Lead sponsor
- XOMA (US) LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Escondido, California • Miami Gardens, Florida • Omaha, Nebraska + 1 more
- Conditions
- SARS-CoV-2
- Interventions
- ADM03820, Placebo
- Drug · Other
- Lead sponsor
- Alachua Government Services, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina • San Antonio, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Bakersfield, California • Encinitas, California + 30 more
- Conditions
- Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
- Interventions
- DC vaccine, Celecoxib, Interferon Alfa-2b, rintatolimod
- Biological · Drug
- Lead sponsor
- David Bartlett
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- VX-407, Placebo, Midazolam
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Advanced Solid Tumor, Colorectal Cancer
- Interventions
- TORL-3-600
- Drug
- Lead sponsor
- TORL Biotherapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Fullerton, California • Los Angeles, California • Denver, Colorado + 4 more
- Conditions
- Healthy Volunteers (HV)
- Interventions
- Investigational Drug: IBI3042, Matching Placebo
- Drug
- Lead sponsor
- Fortvita Biologics (USA)Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Solid Tumor, Advanced Solid Tumor
- Interventions
- IMP9064
- Drug
- Lead sponsor
- Impact Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • New York, New York • Greenville, South Carolina + 1 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- irinotecan hydrochloride
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Interventions
- Radiation therapy, Leuprolide, Relugolix
- Radiation · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Gout, Hyperuricemia
- Interventions
- ABP-671, Placebo
- Drug · Other
- Lead sponsor
- Atom Therapeutics Co., Ltd
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona